Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Ranibizumab Launch - Midas Pharma is the Marketing Authorisation Holder (MAH) of a Biosimilar
Details : Ranivisio (ranibizumab) is a VEGF-A inhibitor, which is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, and diabetic macular edema.
Product Name : Ranivisio
Product Type : Antibody
Upfront Cash : Inapplicable
November 10, 2023
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bisoprolol Fumarate,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : Apontis Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The aim of the partnership is the contract development of a Single Pill, Biramlo, with a combination of two leading active ingredients,bisoprolol fumarate and amlodipine for the treatment of high blood pressure (hypertension).
Product Name : Biramlo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 19, 2022
Lead Product(s) : Bisoprolol Fumarate,Amlodipine
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : Apontis Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EMA CHMP Recommends Grant of Marketing Authorization of Ranibizumab Biosimilar
Details : The active substance of Ranivisio is ranibizumab, a monoclonal antibody fragment (ATC code: S01LA04) which modulates angiogenesis by inhibiting vascular endothelial growth factor A. Ranivisio is a biosimilar medicinal product.
Product Name : Ranivisio
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2022
Lead Product(s) : Ranibizumab
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Recipient : Apontis Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Details : The objective is the contract development of a Single Pill with a combination of three leading active ingredients, including candesartan cilexetil, amlodipine besylate and atorvastatin calcium trihydrate for the treatment of high blood pressure (hyperten...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 14, 2021
Lead Product(s) : Candesartan Cilexetil,Amlodipine Besylate,Atorvastatin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Recipient : Apontis Pharma
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : Pharmacare Premium
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Vorient-Generic (pazopanib) is a kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma & advanced soft tissue sarcoma who have received prior chemotherapy.
Product Name : Vorient-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 26, 2021
Lead Product(s) : Pazopanib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : Pharmacare Premium
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Coripharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Coripharma and Midas Have Entered into an Exclusive Licensing Partnership
Details : Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.
Product Name : Raltegravir-Generic
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
September 23, 2020
Lead Product(s) : Raltegravir Potassium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Coripharma
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ramipril
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-drug-interaction Study of Ramipril, Amlodipine and Atorvastatin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 10, 2020
Lead Product(s) : Ramipril
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 28, 2020
Lead Product(s) : Candesartan Cilexetil
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable